Scientists are conducting a phase I clinical trial combining NK cell therapy with an immunocytokine to target children with relapsed/refractory neuroblastoma. The treatment aims to kill cancer cells in a less toxic way than conventional therapies.
A new transatlantic Phase 1 clinical trial for neuroblastoma is open in the UK, combining targeted radiation therapy with antibodies Nivolumab and Dinutuximab beta to enhance immune response. The study aims to prove the combination's effectiveness in boosting children's long-term immunity against their disease.
A phase 1 clinical trial has opened enrollment for children aged 12 and above, leveraging a re-engineered polio virus to treat high-grade brain tumors. Dramatic responses have been seen in adult trial participants, paving the way for this innovative therapy to be tested in pediatric patients.
A collaborative clinical trial will test the safety and efficacy of combination checkpoint inhibitors in treating children with brain tumors. The trial aims to reduce toxicities associated with standard treatments and improve long-term survival rates.
The INBRACED initiative has awarded a $400,000 grant to launch an international phase I clinical trial for children with relapsed or refractory neuroblastoma. The vaccine targets the GD2 and GD3 antigens and has shown promising results in children with neuroblastoma in the US.
A new clinical trial combines NK cell therapy with an immunocytokine to target children with relapsed/refractory neuroblastoma, promising a less toxic treatment option. Researchers at the University of Wisconsin-Madison will use haploidentical natural killer cells infused with hu14.18-IL2 to destroy cancer cells.
A new dendritic cell vaccine has been shown to induce complete remission in a six-year-old boy with recurrent neuroblastoma. The vaccine uses cancer-specific targets to stimulate the immune system and attack tumor cells.